Digital PCR Improves Sensitivity and Quantification in Monitoring CAR-T Cells in B Cell Lymphoma Patients

Area of Science:

• Immunotherapy
• Molecular Diagnostics
• Oncology

Background:

• Chimeric antigen receptor T cell (CAR-T) therapy shows promise but faces challenges with long-term patient response, with over 60% experiencing treatment failure.
• Understanding CAR-T cell persistence and effective monitoring are crucial for successful therapeutic outcomes.
• Current monitoring methods like multiparametric flow cytometry (MFC) and quantitative PCR (qPCR) have limitations in sensitivity and scope.

Purpose of the Study:

• To develop and validate digital PCR (dPCR) assays for detecting and quantifying CAR-T cells.
• To compare the performance of dPCR assays against established methods, MFC and qPCR.
• To evaluate the clinical utility of dPCR for monitoring CAR-T cell dynamics in patients.

Main Methods:

• Development of novel digital PCR (dPCR) assays for CAR-T cell detection and quantification.
• Analysis of samples from 45 patients undergoing CAR-T therapy at various follow-up time points.
• Comparative analysis of dPCR results against multiparametric flow cytometry (MFC) and quantitative PCR (qPCR) data.

Main Results:

• dPCR assays demonstrated a high correlation with MFC (r = 0.97) and qPCR (r = 0.87).
• dPCR exhibited superior sensitivity (0.01%) compared to MFC (0.1%) and qPCR (1%).
• The study confirmed dPCR as a sensitive and reliable method for tracking CAR-T cell levels.

Conclusions:

• Digital PCR (dPCR) is a highly sensitive and accurate alternative for monitoring CAR-T cell dynamics.
• dPCR offers improved sensitivity over MFC and qPCR, aiding in the assessment of therapeutic efficacy.
• dPCR is suitable for clinical implementation as a complementary tool for CAR-T therapy monitoring.